Clinical ResearchInterventional CardiologyA Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions: The SOS (Stenting Of Saphenous Vein Grafts) Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
The SOS (Stenting Of Saphenous Vein Grafts) trial was funded by a Veterans Affairs VISN-17 Startup Award, and by the Clark R. Gregg fund of the Harris Methodist Foundation to Dr. Brilakis. Dr. Brilakis has received speaker honoraria from St. Jude. Dr. Obel works predominantly with cardial rhythm devices and has speaker agreements with St. Jude, Medtronic, and Boston Scientific. Dr. Rossen participated in multicenter clinical studies supported by Boston Scientific. Dr. Berger has spoken at CME-approved scientific symposia supported by Bristol-Myers Squibb/Sanofi-Aventis, the Medicines Company, AstraZeneca, Medtronic, and Eli Lilly/Daiichi-Sankyo (each for <$10,000); served as a consultant to PlaCor, Eli Lilly, Accumetrics, The Medicines Company, and Eli Lilly/Daiichi-Sankyo (each for <$10,000); and owns equity in Lumen, Inc. (a company that is developing an embolic protection device) (>$10,000). Dr. Banerjee has served on the Speakers' Bureau for St. Jude Medical Center, Medtronic Corp., and Johnson & Johnson and has received a research grant from Boston Scientific. The SOS trial was presented as a late-breaking trial at the TCT 2008 meeting in Washington, DC, in October 2008.